keyword
MENU ▼
Read by QxMD icon Read
search

proteome, antidepressant

keyword
https://www.readbyqxmd.com/read/29150633/ketamine-s-antidepressant-effect-is-mediated-by-energy-metabolism-and-antioxidant-defense-system
#1
Katja Weckmann, Michael J Deery, Julie A Howard, Renata Feret, John M Asara, Frederik Dethloff, Michaela D Filiou, Jamie Iannace, Christiana Labermaier, Giuseppina Maccarrone, Christian Webhofer, Larysa Teplytska, Kathryn Lilley, Marianne B Müller, Christoph W Turck
Fewer than 50% of all patients with major depressive disorder (MDD) treated with currently available antidepressants (ADs) show full remission. Moreover, about one third of the patients suffering from MDD does not respond to conventional ADs and develop treatment-resistant depression (TRD). Ketamine, a non-competitive, voltage-dependent N-Methyl-D-aspartate receptor (NMDAR) antagonist, has been shown to have a rapid antidepressant effect, especially in patients suffering from TRD. Hippocampi of ketamine-treated mice were analysed by metabolome and proteome profiling to delineate ketamine treatment-affected molecular pathways and biosignatures...
November 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29094313/progress-in-elucidating-biomarkers-of-antidepressant-pharmacological-treatment-response-a-systematic-review-and-meta-analysis-of-the-last-15-years
#2
REVIEW
G Voegeli, M L Cléry-Melin, N Ramoz, P Gorwood
BACKGROUND: Antidepressant drugs are widely prescribed, but response rates after 3 months are only around one-third, explaining the importance of the search of objectively measurable markers predicting positive treatment response. These markers are being developed in different fields, with different techniques, sample sizes, costs, and efficiency. It is therefore difficult to know which ones are the most promising. OBJECTIVE: Our purpose was to compute comparable (i...
November 2, 2017: Drugs
https://www.readbyqxmd.com/read/29021832/pharmacogenomics-in-the-treatment-of-mood-disorders-strategies-and-opportunities-for-personalized-psychiatry
#3
REVIEW
Azmeraw T Amare, Klaus Oliver Schubert, Bernhard T Baune
Personalized medicine (personalized psychiatry in a specific setting) is a new model towards individualized care, in which knowledge from genomics and other omic pillars (microbiome, epigenomes, proteome, and metabolome) will be combined with clinical data to guide efforts to new drug development and targeted prescription of the existing treatment options. In this review, we summarize pharmacogenomic studies in mood disorders that may lay the foundation towards personalized psychiatry. In addition, we have discussed the possible strategies to integrate data from omic pillars as a future path to personalized psychiatry...
September 2017: EPMA Journal
https://www.readbyqxmd.com/read/28993683/short-term-changes-in-the-proteome-of-human-cerebral-organoids-induced-by-5-meo-dmt
#4
Vanja Dakic, Juliana Minardi Nascimento, Rafaela Costa Sartore, Renata de Moraes Maciel, Draulio B de Araujo, Sidarta Ribeiro, Daniel Martins-de-Souza, Stevens K Rehen
Dimethyltryptamines are entheogenic serotonin-like molecules present in traditional Amerindian medicine recently associated with cognitive gains, antidepressant effects, and changes in brain areas related to attention. Legal restrictions and the lack of adequate experimental models have limited the understanding of how such substances impact human brain metabolism. Here we used shotgun mass spectrometry to explore proteomic differences induced by 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) on human cerebral organoids...
October 9, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28963507/peroxiredoxin-6-mediates-g%C3%AE-i-protein-coupled-receptor-inactivation-by-cjun-kinase
#5
Selena S Schattauer, Benjamin B Land, Kathryn L Reichard, Antony D Abraham, Lauren M Burgeno, Jamie R Kuhar, Paul E M Phillips, Shao En Ong, Charles Chavkin
Inactivation of opioid receptors limits the therapeutic efficacy of morphine-like analgesics and mediates the long duration of kappa opioid antidepressants by an uncharacterized, arrestin-independent mechanism. Here we use an iterative, discovery-based proteomic approach to show that following opioid administration, peroxiredoxin 6 (PRDX6) is recruited to the opioid receptor complex by c-Jun N-terminal kinase (JNK) phosphorylation. PRDX6 activation generates reactive oxygen species via NADPH oxidase, reducing the palmitoylation of receptor-associated Gαi in a JNK-dependent manner...
September 29, 2017: Nature Communications
https://www.readbyqxmd.com/read/28912679/proteomic-differences-in-blood-plasma-associated-with-antidepressant-treatment-response
#6
Christoph W Turck, Paul C Guest, Giuseppina Maccarrone, Marcus Ising, Stefan Kloiber, Susanne Lucae, Florian Holsboer, Daniel Martins-de-Souza
The current inability of clinical psychiatry to objectively select the most appropriate treatment is a major factor contributing to the severity and clinical burden of major depressive disorder (MDD). Here, we have attempted to identify plasma protein signatures in 39 MDD patients to predict response over a 6-week treatment period with antidepressants. LC-MS/MS analysis showed that differences in the levels of 29 proteins at baseline were found in the group with a favorable treatment outcome. Most of these proteins were components of metabolism or immune response pathways as well as multiple components of the coagulation cascade...
2017: Frontiers in Molecular Neuroscience
https://www.readbyqxmd.com/read/28860968/differential-peripheral-proteomic-biosignature-of-fluoxetine-response-in-a-mouse-model-of-anxiety-depression
#7
Indira Mendez-David, Céline Boursier, Valérie Domergue, Romain Colle, Bruno Falissard, Emmanuelle Corruble, Alain M Gardier, Jean-Philippe Guilloux, Denis J David
The incorporation of peripheral biomarkers in the treatment of major depressive disorders (MDD) could improve the efficiency of treatments and increase remission rate. Peripheral blood mononuclear cells (PBMCs) represent an attractive biological substrate allowing the identification of a drug response signature. Using a proteomic approach with high-resolution mass spectrometry, the present study aimed to identify a biosignature of antidepressant response (fluoxetine, a Selective Serotonin Reuptake Inhibitor) in PBMCs in a mouse model of anxiety/depression...
2017: Frontiers in Cellular Neuroscience
https://www.readbyqxmd.com/read/28709695/peripheral-biomarkers-of-major-depression-and-antidepressant-treatment-response-current-knowledge-and-future-outlooks
#8
REVIEW
Bharathi S Gadad, Manish K Jha, Andrew Czysz, Jennifer L Furman, Taryn L Mayes, Michael P Emslie, Madhukar H Trivedi
BACKGROUND: In recent years, we have accomplished a deeper understanding about the pathophysiology of major depressive disorder (MDD). Nevertheless, this improved comprehension has not translated to improved treatment outcome, as identification of specific biologic markers of disease may still be crucial to facilitate a more rapid, successful treatment. Ongoing research explores the importance of screening biomarkers using neuroimaging, neurophysiology, genomics, proteomics, and metabolomics measures...
July 5, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28628884/proteomics-profiling-reveals-inflammatory-biomarkers-of-antidepressant-treatment-response-findings-from-the-co-med-trial
#9
Bharathi S Gadad, Manish K Jha, Bruce D Grannemann, Taryn L Mayes, Madhukar H Trivedi
Animal and human studies suggest an association between depression and aberrant immune response. Further, common inflammatory markers may change during the course of antidepressant treatment in patients. The objective of this study was to evaluate changes in inflammatory markers and clinical outcomes from subjects enrolled in the Combining Medications to Enhance Depression Outcome (CO-MED) trial. At baseline and week 12 (treatment completion), plasma samples of 102 participants were analyzed via a multiplex assay comprised of inflammatory markers using a 27-plex standard assay panel plus a 4-plex human acute phase xMAP technology based platform...
November 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/28529691/recent-advances-in-predicting-responses-to-antidepressant-treatment
#10
REVIEW
Thomas Frodl
Major depressive disorder is one of the leading causes of disability in the world since depression is highly frequent and causes a strong burden. In order to reduce the duration of depressive episodes, clinicians would need to choose the most effective therapy for each individual right away. A prerequisite for this would be to have biomarkers at hand that would predict which individual would benefit from which kind of therapy (for example, pharmacotherapy or psychotherapy) or even from which kind of antidepressant class...
2017: F1000Research
https://www.readbyqxmd.com/read/28526399/evaluation-of-the-effectiveness-of-chronic-antidepressant-drug-treatments-in-the-hippocampal-mitochondria-a-proteomic-study-in-an-animal-model-of-depression
#11
Katarzyna Głombik, Aneta Stachowicz, Ewa Trojan, Rafał Olszanecki, Joanna Ślusarczyk, Maciej Suski, Katarzyna Chamera, Bogusława Budziszewska, Władysław Lasoń, Agnieszka Basta-Kaim
Several lines of evidence indicate that adverse experience in early life may be a triggering factor for disturbances in the brain mitochondrial proteins and lead to the development of depression in adulthood. On the other hand, little is known about the impact of chronic administration of various antidepressant drugs on the brain mitochondria, as a target for the pharmacotherapy of depression. The purpose of our study was to compare the impact of chronic treatment with two antidepressant drugs with different mechanisms of action, a tricyclic antidepressant (TCA), imipramine, and an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class, fluoxetine, on the mitochondria-enriched subproteome profile in the hippocampus of 3-month-old male rats following a prenatal stress procedure (an animal model of depression)...
August 1, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28375208/delineation-of-molecular-pathway-activities-of-the-chronic-antidepressant-treatment-response-suggests-important-roles-for-glutamatergic-and-ubiquitin-proteasome-systems
#12
D I Park, C Dournes, I Sillaber, M Ising, J M Asara, C Webhofer, M D Filiou, M B Müller, C W Turck
The aim of this study was to identify molecular pathways related to antidepressant response. We administered paroxetine to the DBA/2J mice for 28 days. Following the treatment, the mice were grouped into responders or non-responders depending on the time they spent immobile in the forced swim test. Hippocampal metabolomics and proteomics analyses revealed that chronic paroxetine treatment affects glutamate-related metabolite and protein levels differentially in the two groups. We found significant differences in the expression of N-methyl-d-aspartate receptor and neuronal nitric oxide synthase proteins between the two groups, without any significant alterations in the respective transcript levels...
April 4, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/28017803/ca-2-dependent-surface-trafficking-of-norepinephrine-transporters-depends-on-threonine-30-and-ca-2-calmodulin-kinases
#13
Uhna Sung, Francesca Binda, Valentina Savchenko, William A Owens, Lynette C Daws
The antidepressant-sensitive norepinephrine (NE) transporter (NET) inactivates NE released during central and peripheral neuronal activity by transport into presynaptic cells. Altered NE clearance due to dysfunction of NET has been associated with the development of mental illness and cardiovascular diseases. NET activity in vivo is influenced by stress, neuronal activity, hormones and drugs. We investigated the mechanisms of Ca(2+) regulation of NET and found that Ca(2+) influenced both Vmax and Km for NE transport into cortical synaptosomes...
October 2017: Journal of Chemical Neuroanatomy
https://www.readbyqxmd.com/read/27731396/purine-and-pyrimidine-metabolism-convergent-evidence-on-chronic-antidepressant-treatment-response-in-mice-and-humans
#14
Dong Ik Park, Carine Dournes, Inge Sillaber, Manfred Uhr, John M Asara, Nils C Gassen, Theo Rein, Marcus Ising, Christian Webhofer, Michaela D Filiou, Marianne B Müller, Christoph W Turck
Selective Serotonin Reuptake Inhibitors (SSRIs) are commonly used drugs for the treatment of psychiatric diseases including major depressive disorder (MDD). For unknown reasons a substantial number of patients do not show any improvement during or after SSRI treatment. We treated DBA/2J mice for 28 days with paroxetine and assessed their behavioral response with the forced swim test (FST). Paroxetine-treated long-time floating (PLF) and paroxetine-treated short-time floating (PSF) groups were stratified as proxies for drug non-responder and responder mice, respectively...
October 12, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27612656/systems-biology-integration-of-proteomic-data-in-rodent-models-of-depression-reveals-involvement-of-the-immune-response-and-glutamatergic-signaling
#15
Lucia Carboni, Thanh-Phuong Nguyen, Laura Caberlotto
PURPOSE: The pathophysiological basis of major depression is incompletely understood. Recently, numerous proteomic studies have been performed in rodent models of depression to investigate the molecular underpinnings of depressive-like behaviours with an unbiased approach. The objective of the study is to integrate the results of these proteomic studies in depression models to shed light on the most relevant molecular pathways involved in the disease. EXPERIMENTAL DESIGN: Network analysis is performed integrating preexisting proteomic data from rodent models of depression...
December 2016: Proteomics. Clinical Applications
https://www.readbyqxmd.com/read/27605454/the-extrinsic-coagulation-pathway-a-biomarker-for-suicidal-behavior-in-major-depressive-disorder
#16
Yongtao Yang, Jin Chen, Chengyu Liu, Liang Fang, Zhao Liu, Jing Guo, Ke Cheng, Chanjuan Zhou, Yuan Zhan, Narayan D Melgiri, Liang Zhang, Jiaju Zhong, Jianjun Chen, Chenglong Rao, Peng Xie
Although an association between major depressive disorder (MDD) and suicide exists, most depressed patients never attempt suicide. An improved understanding of the factors contributing to suicidal risk in MDD can provide direction for suicide predictor development. In MDD suicide attempters (MDD-SA), MDD non-attempters (MDD-NA), and healthy controls (HC) (n = 12 each group), complementary plasma proteomics identified 45 differential proteins mapped to coagulation and inflammation, 25 of which underwent Western blotting...
September 8, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27378857/effects-of-fluoxetine-on-human-embryo-development
#17
Helena Kaihola, Fatma G Yaldir, Julius Hreinsson, Katarina Hörnaeus, Jonas Bergquist, Jocelien D A Olivier, Helena Åkerud, Inger Sundström-Poromaa
The use of antidepressant treatment during pregnancy is increasing, and selective serotonin reuptake inhibitors (SSRIs) are the most widely prescribed antidepressants in pregnant women. Serotonin plays a role in embryogenesis, and serotonin transporters are expressed in two-cell mouse embryos. Thus, the aim of the present study was to evaluate whether fluoxetine, one of the most prescribed SSRI antidepressant world-wide, exposure influences the timing of different embryo developmental stages, and furthermore, to analyze what protein, and protein networks, are affected by fluoxetine in the early embryo development...
2016: Frontiers in Cellular Neuroscience
https://www.readbyqxmd.com/read/27371348/proteomic-investigation-of-the-prefrontal-cortex-in-the-rat-clomipramine-model-of-depression
#18
Barbara Gellén, Katalin Völgyi, Balázs András Györffy, Zsuzsa Darula, Éva Hunyadi-Gulyás, Péter Baracskay, András Czurkó, István Hernádi, Gábor Juhász, Árpád Dobolyi, Katalin Adrienna Kékesi
Neonatal rodents chronically treated with the tricyclic antidepressant clomipramine show depression-like behavior, which persists throughout adulthood. Therefore, this animal model is suitable to investigate the pathomechanism of depression, which is still largely unknown at the molecular level beyond monoaminergic dysfunctions. Here, we describe protein level changes in the prefrontal cortex of neonatally clomipramine-treated adult rats correlating with behavioral abnormalities. Clomipramine was administered to rat pups twice daily between postnatal days 8-21, while controls received saline injections...
February 5, 2017: Journal of Proteomics
https://www.readbyqxmd.com/read/27084692/discovering-biomarkers-for-antidepressant-response-protocol-from-the-canadian-biomarker-integration-network-in-depression-can-bind-and-clinical-characteristics-of-the-first-patient-cohort
#19
MULTICENTER STUDY
Raymond W Lam, Roumen Milev, Susan Rotzinger, Ana C Andreazza, Pierre Blier, Colleen Brenner, Zafiris J Daskalakis, Moyez Dharsee, Jonathan Downar, Kenneth R Evans, Faranak Farzan, Jane A Foster, Benicio N Frey, Joseph Geraci, Peter Giacobbe, Harriet E Feilotter, Geoffrey B Hall, Kate L Harkness, Stefanie Hassel, Zahinoor Ismail, Francesco Leri, Mario Liotti, Glenda M MacQueen, Mary Pat McAndrews, Luciano Minuzzi, Daniel J Müller, Sagar V Parikh, Franca M Placenza, Lena C Quilty, Arun V Ravindran, Tim V Salomons, Claudio N Soares, Stephen C Strother, Gustavo Turecki, Anthony L Vaccarino, Fidel Vila-Rodriguez, Sidney H Kennedy
BACKGROUND: Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers ("biomarkers") of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that help to predict outcomes in patients with MDD treated with antidepressant medication...
April 16, 2016: BMC Psychiatry
https://www.readbyqxmd.com/read/26423280/proteomic-changes-in-corbicula-fluminea-exposed-to-wastewater-from-a-psychiatric-hospital
#20
M J Bebianno, S Sroda, T Gomes, P Chan, E Bonnafe, H Budzinski, F Geret
The increase use of pharmaceutical compounds in veterinary practice and human population results in the ubiquitous presence of these compounds in aquatic ecosystems. Because pharmaceuticals are highly bioactive, there is concern about their toxicological effects in aquatic organisms. Therefore, the aim of this study was to assess the effects of an effluent from a psychiatric hospital (containing a complex mixture of 25 pharmaceutical compounds from eleven therapeutic classes) on the freshwater clam Corbicula fluminea using a proteomic approach...
March 2016: Environmental Science and Pollution Research International
keyword
keyword
80220
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"